newsfilter
← Earnings
Earnings Releases·

Humacyte — Third Quarter 2026 Earnings Summary

Humacyte reported third-quarter 2026 commercial sales of $1.0 million for its Symvess product, representing a 151% increase over the second quarter and a 44% expansion in hospital adoption. The company plans to file a Supplemental Biologics License Application with the FDA in November 2026 to add dialysis access as a new indication for its Acellular Tissue Engineered Vessel (ATEV), supported by positive Phase 3 trial results. Additionally, Humacyte initiated a first-in-human Phase 2a clinical study for its Coronary Tissue Engineered Vessel (CTEV) in coronary artery bypass grafting. For the nine months ended September 30, 2026, the company recorded a net loss of $70.0 million while maintaining $64.9 million in cash and cash equivalents.

Company
HUMACYTE INC
Sector
Healthcare
Industry
Biotechnology